Infertility Clinical Trial
Official title:
Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest
This study aims at investigating the fertility outcome of endometriosis suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month in endometriosis patients stage I and II.
Study population: Sample size:
Group sample sizes of this study is 155 in group one and 155 in group two achieve 80% power
to detect a difference between the group proportions of 0.10. The proportion in group one
(the treatment group) is assumed to be 0.1000 under the null hypothesis and 0.2000 under the
alternative hypothesis. The proportion in group two (the control group) is 0.1000. The test
statistic used is .the one-sided Z test with un pooled variance. The significance level of
the test was targeted at 0.05
Primary outcome:
Clinical pregnancy rate in endometriosis patients stage I and II undergoing endometriosis
suppression with dienogest 2mg / day for 3 month followed by induction of ovulation for 3
month.
Secondary outcome:
Ovulation rate in endometriosis patients stage I and II undergoing endometriosis suppression
with dienogest 2mg / day for 3 month followed by induction of ovulation for 3 month.
Inclusion criteria:
All women recruited in this study will have the have a definitive diagnosis of endometriosis
grade I or grade II via laparoscopy just before randomization.
Method of Randomization:
A Computerized generated list from the internet
https://www.sealedenvelope.com/sirnple-randomiser/vl/lists
Allocation concealment:
Closed envelope method by a nurse not participating in the study Intervention It is a
prospective randomized controlled trial. Investigation done after recruitment and before
randomization.
The patients will be randomized in to two groups:
Group A: patients receive dienogest 2 mg (visanne 2mg sanofi Aventis) daily for three months
then followed by induction of ovulation with clomiphene citrate (clomid 5mg sanofi aventis
for three months.
Group B: Patients will undergo induction of ovulation with clomiphene citrate (clomid 50mg
sanofi aventis) for three months.
Protocol of induction of ovulation
1. Clomiphen citrate (clomid 50mg sanofi aventis) will be given on day two of the
menstrual cycle at a dose of 50 mg twice daily for five days.
2. Folliculometry will be performed every other day starting from seventh day of the cycle
till ovulation occurs using a 6 Mhz transvaginal probe till the follicles reach 18 - 20
mm.
3. A trigger of ovulation HCG 10000iu is given IM when the follicles reach 18- 22 mm. The
couple will be advised to have intercourse after 36 hrs then daily for 7 days.
4. Prontogest 400 mg (progest 400 mg Sanofi Aventis) daily vaginal suppository as a luteal
phase support.
5. Pregnancy will be diagnosed quantitative B HCG blood test after 2 days missed period.
6. Clinical pregnancy rate will be diagnosed by TVUS confirmed fetal echo with pulsation
at 5-7 weeks gestation.
The sonographer confirming clinical pregnancy will be blinded to both groups. Statistical
Analysis
Statistical Method:
Statistical analysis will be performed using Microsoft Excel version 2010 and statistical
package for social sciences ( SPSS ) for windows version l S.O.
Continious data are to be presented as range, mean and standard deviation (if parametric);
or range; median and inter quartile range (if non - parametric).
Dichotomous or categorical data are to be presented as number and percentage. Difference
between independent is to be estimated using independent student's t-test (for parametric
continuous variables), Manny whitney test U-test (for non -parametric continuous variables)
and Chi-square and test (for categorical variables). Receiver operator characteristics curve
is to be constructed to assess the predictability is to be expressed in terms of sensitivity
, specificity , positive and negative predictive values. Significance level is at 0.05.
Ethical and legal aspects
Delegation of investigator responsibilities:
The investigator will ensure that all persons assisting with the trial are adequately
informed about the protocol, any amendments to the protocol, the study treatments, and their
trial-related duties and functions.
Patient information and informed consent:
Before being admitted to the clinical study, the patient must consent to participate after
the nature, scope and possible consequences of the clinical study have been explained in a
form understandable to her and a written consent will be obtained.
Confidentiality:
Only the patient initials will be recorded in the files, and if the patients name appears on
any other document, it must be kept in a privacy by the investigators. The investigator will
maintain a personal patient identification list (patient initials with the corresponding
patient names) to enable records to be identified.
Protocol approval:
Before the beginning of the study and in accordance with the local regulation followed, the
protocol and all the corresponding documents will be declared for Ethical and Research
approval by the council of the obstetrics Department, Ain Shams University.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A |